Intravascular ultrasound guidance for lower extremity arterial and venous interventions

Eric A. Secemsky^{1,2,3*}, MD; Sahil A. Parikh⁴, MD; Maureen Kohi⁵, MD; Michael Lichtenberg⁶, MD; Mark Meissner⁷, MD; Ramon Varcoe^{8,9,10}, MBBS; Andrew Holden¹¹, MBChB; Michael Jaff², DO; David Chalyan^{12,13}, MD; Daniel Clair¹⁴, MD; Beau Hawkins¹⁵, MD; Kenneth Rosenfield¹⁶, MD

1. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA; 2. Harvard Medical School, Boston, MA, USA; 3. Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; 4. Center for Interventional Vascular Therapy and Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, USA; 5. Department of Radiology, University of North Carolina, Chapel Hill, NC, USA; 6. Clinic for Angiology, Klinikum Arnsberg, Arnsberg, Germany; 7. Department of Surgery, University of Washington School of Medicine, Seattle, WA, USA; 8. Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia; 9. Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia; 10. The Vascular Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia; 11. Department of Interventional Radiology, Auckland City Hospital, Auckland, New Zealand; 12. Department of Radiological Sciences, University of California-Irvine, Irvine, CA, USA; 13. Philips Healthcare, Amsterdam, the Netherlands; 14. Department of Surgery, Vanderbilt University Medical Center, *Nashville, TN, USA; 15. Division of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 16. Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA*

KEYWORDS

Abstract

- •below-the-knee disease
- femoropopliteal disease
- iliac disease
- imaging modalities

This review details the utility of intravascular ultrasound (IVUS) for the management of peripheral artery and venous disease. The purpose of this document is to provide an update in the use of IVUS in peripheral arterial and venous pathology and demonstrate the use of IVUS as a practical diagnostic imaging procedure to evaluate and treat peripheral vascular disorders. IVUS, a diagnostic tool that relies on sound waves to produce precise images of the vessel being evaluated, was originally introduced to the medical community for the purposes of peripheral artery imaging, though it was quickly adapted for coronary interventions with positive outcomes. The utility of IVUS includes vessel measurement, pre- and post-procedural planning, treatment optimisation, and detection of thrombus, dissection or calcium severity. While angiography remains the standard imaging approach during peripheral intervention, multiple observational studies and small prospective trials have shown that in comparison, IVUS provides more accurate imaging detail, which may improve procedural outcomes. IVUS can also address limitations of angiography, including the need to administer contrast medium and eliminate the ambiguity associated with other forms of imaging. This review provides contemporary examples of where IVUS is being used during peripheral intervention as well as representative imaging to serve as a resource for the practising clinician.

**Corresponding author: Smith Center for Outcomes Research in Cardiology, 375 Longwood Avenue, 4th Floor, Boston, MA 02215, USA. E-mail: esecemsk@bidmc.harvard.edu*

Г

Abbreviations

- **CSA** cross-sectional area **CTO** chronic total occlusions
- **DVT** deep vein thrombosis
- **IVUS** intravascular ultrasound
- **LMCA** left main coronary artery
- **MI** myocardial infarction
- **OCT** optical coherence tomography
- **PAD** peripheral artery disease
- **PCI** percutaneous coronary intervention
- **SFA** superficial femoral artery
- **TLR** target lesion revascularisation

VH-IVUS virtual histology IVUS

Introduction

GENERAL BENEFITS AND APPLICATIONS OF IVUS

While initially showing promise in the peripheral arteries¹, the development of evidence establishing intravascular ultrasound (IVUS) use in peripheral arterial and venous intervention has lagged behind that of coronary procedures^{$2-6$}. Recently, however, physicians have increasingly recognised the potential impact of IVUS imaging to improve diagnostic acumen, therapeutic decision-making and outcomes in non-coronary vessels⁷⁻⁹. This has resulted in innovation in IVUS technology and its increased use in peripheral interventions^{10,11}. In this document we aim to review the foundation of IVUS imaging, explore how it gained adoption during percutaneous coronary interventions, describe current applications of IVUS in peripheral vascular interventions and present clinical scenarios in which use of IVUS should be considered.

BASIC PRINCIPLES OF IVUS

The creation of images with IVUS begins with transmission of an electrical current through a piezoelectric transducer, which causes expansion and contraction of the material, thereby generating sound waves. These waves partially reflect off the tissue and return the ultrasound energy to the transducer, generating an electrical impulse that converts into tomographic images. IVUS generates precise images of the anatomic structure (i.e., artery, vein)

pictures displayed in grayscale. However, current iterations include a broader range of frequencies that can produce higher fidelity images and achieve maximum diameter penetration. Additional imaging display options are now available, such as colour (e.g., ChromaFlo; Philips Volcano), to better delineate intraluminal structures. Virtual histology IVUS (VH-IVUS), utilising a low radiofrequency signal, has also been used to better characterise the histologic composition of the vessel wall and associated plaque.

being evaluated, but is dependent on both spatial and contrast

COMMERCIALLY AVAILABLE PRODUCTS

Currently, there are multiple IVUS catheters commercially available for use in the lower extremity vasculature. Many of these were first developed for coronary use but can be used to image similarly sized vessels, such as the tibial arteries. These devices have since been iterated to provide a broader field of view for use in larger vessels, such as the iliac veins and inferior vena cava. Examples of several commercially available peripheral IVUS catheters are displayed in **Table 1**.

VESSEL MEASUREMENTS

One of the most important benefits of IVUS is the ability to accurately measure lumen dimensions. Using IVUS, one can precisely determine lumen diameter, lumen cross-sectional area (CSA) and the size of the reference vessel (e.g., the approximate lumen dimension in the absence of disease). Each measurement can be used to grade severity of disease, size interventional devices and optimise implants. However, differences exist in how to best estimate vessel size (in part due to variations in blood vessel type [i.e., artery and vein]), vessel location, and image quality. This is in part due to a lack of universally accepted standards.

Table 1. Examples of IVUS peripheral catheters.

In conventional angiography, measurement of vessel dimensions comprises multiple factors. First, the measured structure represents a small portion of the overall image, so even a small inaccuracy in calibration will be magnified and lead to large errors in size determination. In contradistinction, IVUS presents a magnified view of the vessel. The segment(s) being interrogated occupies nearly the entire display screen, rather than a fraction as would be the case in angiography. Second, accurate determination of the size of a three-dimensional (3D) structure from a twodimensional (2D) image assumes the vessel is perfectly round, which is often false, such as in the case of eccentric vessel configuration or the presence of eccentric plaque. Similarly, lesions arising from anterior-posterior compression are common in the central veins (e.g., left common iliac and left renal vein compression) and are easily missed on single-plane angiography. Third, angiography only displays images of the lumen, where the contrast is seen, but cannot assess the components, structure or morphology; thus, for example, in the case of diffuse disease, angiography can produce inaccurate assessment of the true size of the reference vessel.

The general approach to measuring a cross-sectional luminal area on IVUS involves identifying the vessel lumen in each segmented axial image, selecting multiple points along the lumen boundary and, then, using the trace function to delineate the vessel lumen **(Figure 1)**. Trace points are automatically or manually selected based on the curvature of the boundary and the local image gradient. The lumen segmentation is complete when the distance between the first and last trace points on the contour is less than the pre-set spacing of the contour points¹³. Sequential cross-sectional images can then be "stacked" digitally to create a longitudinal view together with the detailed cross-sectional wall anatomy. To obtain the best image quality, the catheter must be parallel to the vessel wall and centred within the lumen; minor angulations can affect image accuracy or cause an elliptical view of the lumen. Similarly, eccentric positioning can distort the representation of the wall and the size of the lumen. Other factors affect image quality and accuracy, including frequency of the wavelength, catheter size, depth of penetration, gain and vessel blood flow. Higher frequency wavelengths will generally enhance image quality/fidelity and delineation of intravascular structures and the vessel wall. However, depth of penetration and the resulting field of view is reduced as frequency increases. Thus, a balance must be struck between the catheter size and the highest available frequency that still allows enough depth of penetration to image the entire cross-sectional area.

Importantly, all vessels include 3 layers: intima, media and adventitia. In muscular arteries, these layers may be more visible, and arteries also have internal and external elastic lamina membranes that can be used for arterial sizing. Unlike arteries, veins contain bicuspid valves formed by folds of endothelium supported by a thin layer of connective tissue. Although 81% of individuals have at least 1 valve in the external iliac-common femoral segment¹⁴, they are substantially more common and numerous below the inguinal ligament and must be discerned from other

Figure 1. *IVUS-derived measurements of the lower extremity artery. A) Layers of arterial wall. Intima: this layer may often not be visible with IVUS due to its thinness; media: this layer appears as a dark space as it is made of homogeneous smooth muscle cells and does not reflect ultrasound; adventitia: this layer has "sheets" of collagen that reflect significant ultrasound waves and appears white; B) Maximum vessel diameter: the maximum vessel diameter is made by measuring adventitia to adventitia to obtain the longest diameter through the centre point of the lumen (arrows); C) Minimum lumen diameter: the minimum lumen diameter is made by measuring the intima to intima to get the shortest diameter through the centre point of the lumen; D) Vessel area and plaque burden: in this panel, tracing of the vessel area inclusive of the plaque (green circle) is compared with tracing of the vessel lumen exclusive of the plaque (blue circle).*

intravascular structures. Differences between the structure of arteries and veins are further delineated in **Table 2**.

The burden of atheroma can be indirectly measured using IVUS **(Figure 1, Central illustration)**. Plaque burden may be quantified by measuring the plaque plus media CSA and subtracting the luminal CSA. Of note, these measurements may require modification to adjust for vascular remodelling or compensatory enlargement, otherwise known as the Glagov effect¹⁵. Calcium can also be readily identified by IVUS **(Central illustration)**. Calcific deposits appear as bright echoes that obstruct ultrasound penetration (also known as "acoustic shadowing"). As IVUS does not penetrate calcium, the thickness of calcium cannot be estimated. However, the circumferential arc of calcium can be measured in degrees. Lastly, metallic stent struts are also highly echogenic, depending upon their thickness and composition. For newly deployed stents, apposition of the stent to the vessel wall can be visualised and quantified **(Figure 2)**. Full apposition is defined as sufficiently close contact to preclude blood flow between any strut and the underlying wall.

Table 2. Comparison of arteries and veins.

Euro**Intervention**

CENTRAL **ILLUSTRATION IVUS-guided visualisation of intra-arterial plaque and thrombus.**

A) Fibro-fatty plaque: echolucent, light grey to grey appearance (); B) Fibrous plaque: moderately echogenic, light grey to white (*); C) Deep calcific plaque: highly echogenic, white with acoustic shadowing* (\rightarrow) *, can grade based on arc of involvement (0-360°); D)* Thrombus: echolucent or moderate echogenic, notable encroachment into lumen (\rightarrow) .

REVIEW OF THE EXISTING EVIDENCE BASE: THE CORONARY IVUS EXPERIENCE

IVUS has been used during percutaneous coronary intervention (PCI) for three decades, primarily as an adjunctive diagnostic device to assess lesion characteristics, severity of disease, lumen dimensions and post-stent apposition. Data from large meta-analyses have demonstrated that assessment by angiography with adjunctive IVUS is superior to angiography alone in reducing adverse outcomes after stent implantation. For instance, in a meta-analysis comparing use of IVUS with angiography in >26,000 patients undergoing drug-eluting stent implantation, IVUS guidance was associated with a significantly decreased risk of target lesion revascularisation (TLR), death, myocardial infarction (MI) and stent thrombosis¹⁶. A recent retrospective study of

Figure 2. *IVUS-guided detection of arterial dissections and stent malapposition. A) Dissection: disruption of vessel intima* (\rightarrow) *following atherectomy. Use of colour (e.g., ChromaFlo) can be helpful to identify false and true lumens; B) Fully apposed stent: the stent appears highly echogenic due to metal struts (), which appear bright white with a light fallout behind them. This has a "wagon wheel" appearance. This stent is in contact with the lumen wall circumferentially and appears well expanded (full apposition means stent is in complete contact with the lumen wall. This does not mean that it may not be undersized); C) Stent malapposition: the visualised stent is not in contact with the wall circumferentially, with persistent lumen noted behind stent struts (). In this example, ChromaFlo is used to highlight the flow beneath the stent.*

105,787 Medicare patients undergoing IVUS-guided PCI provided further evidence of benefit, demonstrating that IVUS use was associated with significantly lower mortality, MI and repeat revascularisation, both at 1 year and at median follow-up $(3.7 \text{ years})^{17}$. Coronary IVUS has also been shown to be safe, with few procedural complications and no long-term associated risks¹⁸⁻²⁰. This compelling body of evidence has led to the incorporation of IVUS imaging into coronary interventional guidelines, receiving a Class IIa recommendation for assessment of left main coronary artery (LMCA) disease, and a Class IIb recommendation for assessment of non-LMCA disease, guidance of stent implantation and determination of the mechanism of stent thrombosis²¹. Beyond the guidelines, IVUS is widely accepted as a modality that provides detail not seen on angiography in ostial lesions, bifurcation lesions, stent interface with adjacent vessel (e.g., presence of edge dissections) and segments with overlapping vessels that are hidden angiographically²². Another useful role of IVUS in coronary intervention is to characterise the mechanisms of in-stent restenosis, such as underexpansion or stent compression.

Table 3. Intravascular ultrasound (IVUS) versus angiography to evaluate vessel characteristics.

Characteristics	IVUS	Angiography		
Stenosis	$^{+++}$	$^{++}$		
Plaque morphology	$^{+++}$			
Adherent thrombus	$^{+++}$	$^{+}$		
Dissection	$^{+++}$	$++$		
Calcification	$^{+++}$	$^{+}$		
Flow	\pm	$+++$		
Extrinsic compression	$^{+++}$	$^{++}$		
Stent apposition	$+++$	$++$		
$+$ Fair; $++$ Good; $+++$ Excellent; $-$ Not applicable; \pm Under investigation				

LIMITATIONS OF ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY (OCT) IN PERIPHERAL VESSELS

Angiography has traditionally been used for imaging of the peripheral vascular system, providing 2D images of the vessel lumen and its borders. It is most familiar to operators and often required during intervention. However, angiography alone has multiple limitations. First, interpretation of angiographic images may be limited by vessel tortuosity, branch points and concentric lesions²³. Second, angiography may underestimate anatomical features, such as lesion length, the presence of diffuse atheroma and disease features (like plaque morphology or presence of dissections and thrombus)7,24. Third, drawbacks of angiography include increased procedural time, radiation exposure and the need for administration of iodinated contrast²⁵. **Table 3** is a summary of the strengths of IVUS compared with angiography to evaluate peripheral vascular disease.

OCT, while an emerging imaging modality in the coronary space, has limited evidence for use in the periphery. When compared with IVUS, OCT may be able to visualise plaque and vessel characteristics with higher resolution and provide longer pull-back lengths at faster speeds²⁶. However, its use is restricted due to the requirement for contrast injection to clear the blood from the vessel lumen. This compromises the ability to acquire OCT images in larger vessels, in particular those >5 mm in diameter²⁷, and creates liability among patients with renal insufficiency. However, certain groups have used non-contrast solutions with some success $27,28$.

LIMITATIONS OF PERIPHERAL IVUS

IVUS also has limitations which may influence its use. IVUS can be complex to set up and interpret for operators who are not familiar with this technology. This can result in longer procedure times and heterogeneity in how image interpretation influences subsequent treatment. Furthermore, catheter delivery can be challenging when using contralateral access or crossing severely stenosed or long lesions. Lastly, reimbursement for IVUS varies by country and may not cover the full costs of this technology.

598-608

Analysis of current utilisation of IVUS in noncoronary vessels

Within the lower extremity vasculature, IVUS can play a multifaceted role in peripheral interventions. Below, the current use of IVUS during both peripheral arterial and venous interventions and the evidence to support its use will be discussed in detail.

PERIPHERAL ARTERY DISEASE

DIAGNOSIS

Plaque morphology (Central illustration)

IVUS is useful in the evaluation of plaque morphology, which may dictate therapy and predict long-term outcomes. IVUS-detected plaque morphology has been used to evaluate lesion volume and composition, before and after treatment with atherectomy29-32, and to predict risk of amputation³³. With image processing tools that translate echogenicity into profiles for different tissues, IVUS can subclassify plaques into 4 major categories: 1) fibrous, 2) fibrofatty, 3) necrotic-lipid and 4) calcific³⁴. As in coronary arteries, IVUS can also be used to interrogate and define suspected lesions that are ambiguous on angiography.

Detection of calcium severity (Central illustration)

IVUS is particularly sensitive in the detection of calcium⁶ and has a unique role in identifying and grading the degree of vascular calcification. These data may then be used to guide treatment strategies, such as upfront plaque modification with atherectomy or intravascular lithotripsy. IVUS has been used to validate 3 angiographic scoring systems (Peripheral Academic Research Consortium [PARC]³⁵, Peripheral Arterial Calcium Scoring System [PACSS]³⁶, and the DEFINITIVE Ca++trial)³⁷ (Table 4). Notably, in a study of 47 patients undergoing angiographic and IVUS imaging for assessment of peripheral artery calcification, IVUS detected calcium in 44/47 (93.6%) lesions, whereas angiography alone detected calcium in only $26/47$ (55.3%) lesions³⁸. The degree of calcification as evaluated by IVUS has also been shown to predict lumen gain after endovascular therapy of the superficial femoral artery (SFA), with severe calcification in a $\geq 180^\circ$ arc associated with suboptimal vessel preparation. In a retrospective review of 130 patients with symptomatic *de novo* SFA lesions who had successful intervention, IVUS-assessed circumferential distribution of calcium (<180° or \geq 180°) was independently associated

with lumen gain. The rate of restenosis was higher in patients with calcification ≥180°, and the severity of calcification was associated with the risk of stent malapposition³⁹.

Detection of thrombus (Central illustration)

IVUS is useful in identifying fresh, acute and non-occlusive thrombus because of the high concentration of red blood cells and low fibrin deposition⁷. In the DETHROMBOSIS study evaluating the role of the invasive treatment of subacute or recently occluded femoropopliteal lesions, 16/17 (94%) patients had thrombus identified by IVUS whereas only 7/17 (41%) patients had thrombus identified on angiography alone⁴⁰.

PROCEDURAL PLANNING **(Figure 1)**

IVUS can effectively be used for procedural planning to better evaluate lesion characteristics and strategise the optimal approach for treatment, as described above. Furthermore, IVUS has been validated as an effective tool to measure vessel size and length, as well as to evaluate the degree of stenosis both before and after intervention^{$41,42$}. This is notable as angiography alone has been shown to underestimate true lumen size⁴³, which may have a significant impact on long-term outcomes. IVUS can also improve the rate of crossing chronic total occlusions (CTO) by facilitating luminal guidewire crossing and assisting in re-entry techniques⁴⁴⁻⁴⁶. POST-INTERVENTION EVALUATION AND OPTIMISATION

Dissections (Figure 2)

One of the most established roles of IVUS, after peripheral intervention, is identifying and classifying post-treatment arterial dissections⁴⁷. Traditionally, dissections have been assessed and graded by angiography alone. The iDissection study demonstrated that IVUS identified 4-6 times more dissections in above-the-knee arteries than angiography alone^{48,49}. Similar findings have been demonstrated in arteries below the knee⁵⁰. A proposed IVUS-based classification system categorises the severity of arterial dissections of infrainguinal lesions51 **(Table 5)**. The severity of dissections can then predict short-term outcomes along with long-term patency and may help guide treatment options $52,53$.

Stent optimisation (Figure 2)

IVUS is well established in optimising stent expansion and apposition. In one study, IVUS following procedural completion found that 27% of iliac artery stents were incompletely expanded, poorly apposed or had an associated mechanical disruption despite

Table 4. Calcium scoring systems: Peripheral Academic Research Consortium (PARC), Peripheral Arterial Calcium Scoring System (PACSS), and DEFINITIVE Ca++.

Grade	DEFINITIVE Ca++37	PARC ³⁵	Grade	PACSS ³⁶
None			0	No visible calcium at target lesion site
Focal		$\langle 180^\circ (1) \rangle$ side of vessel) and $\langle 1/2 \rangle$ of total lesion length		Unilateral calcification $<$ 5 cm [*]
Mild		$\langle 180^\circ$ and $>1/2$ of total lesion length	2	Unilateral calcification ≥5 cm*
Moderate	Radiopacities on 1 side of arterial wall or $<$ 1 cm in length	\geq 180 $^{\circ}$ (both sides of vessel at same location) and $\lt\frac{1}{2}$ of total lesion length	3	Bilateral calcification $<$ 5 cm [*]
Severe	Radiopacities on both sides of arterial wall, extending >1 cm in length	>180° (both sides of vessel at same location) and $>1/2$ of total lesion length	4	Bilateral calcification \geq 5 cm
*Subtype: a) intimal calcification; b) medial calcification; c) mixed type				

Table 5. iDissection classification 51.

a normal completion arteriogram⁵⁴. These findings translate into worse clinical outcomes, both in the short and long term. For instance, in a retrospective study evaluating the primary patency of nitinol femoropopliteal stents placed with versus without IVUS guidance, IVUS-guided stenting was associated with a significantly higher rate of primary patency at 5 years⁵⁵.

Predictors of long-term outcomes

IVUS may identify factors post-intervention that are associated with greater risks of target lesion failure or stent occlusion. Several studies have demonstrated that following femoropopliteal artery balloon angioplasty, residual stenosis, dissection and lumen area as determined by IVUS are predictive of long-term patency $56,57$. Among patients undergoing stent implantation, IVUS-determined predictors of stent occlusion include minimum stent area, presence of edge dissection and residual plaque burden⁵⁸⁻⁶³.

PERIPHERAL VENOUS DISEASE

In the venous system, IVUS has the greatest utility in the management of obstructive lesions of the iliofemoral venous segment, although it may also be useful in evaluating obstructions of the central upper extremity veins, inferior vena cava and the left renal vein ("nutcracker syndrome"). Chronic obstructive lesions of the inferior vena cava and iliac veins may arise from extrinsic compression by adjacent arterial structures and mass lesions or from post-thrombotic disease. Similar to its use in PAD, IVUS can be used to diagnose, plan and optimise peripheral venous interventions. As the central veins are of substantially larger calibre than the peripheral arteries and large sheaths are required for most interventions, lower-frequency catheters (~10 MHZ) with greater depth penetration are most often utilised.

DIAGNOSIS (Figure 3)

IVUS is considered the "gold standard" for identifying venous iliofemoral lesions⁶⁴. IVUS is particularly useful in quantifying the degree of venous obstruction, especially from lesions arising from extrinsic compression. Not only do many veins often have an elliptical configuration under conditions of normal pressure, but many compressive lesions also occur in an anterior-posterior plane and are easily missed by single-plane angiography. The severity of such eccentric lesions is better reflected by the cross-sectional area reduction with IVUS than by diameter reduction with angi $ography⁶⁴$. For example, in a study of 345 consecutive limbs with suspected common iliac vein obstruction, venography underestimated the median degree of stenosis by 30% in comparison with IVUS, and the sensitivity of venography in comparison with IVUS for detection of a greater than 70% stenosis was only 45%⁶⁵. In another study comparing multiplanar venography and IVUS in 100 patients with advanced chronic venous disease, significant venous obstructive lesions were identified in only 51% of patients by venography versus 81% by IVUS⁶⁶.

In addition to improved quantification of luminal stenosis, IVUS has further value in identifying intraluminal features not seen on venography, such as mural thickening, residual thrombus, synechia, trabeculation and frozen valves⁶⁵. A previous deep vein thrombosis (DVT) is suggested by findings of diffuse narrowing, wall thickening or intraluminal echogenic material⁶⁴.

Although IVUS may be the "gold standard" for identifying venous obstructive lesions, as an isolated measure it is not sufficiently predictive of clinical improvement to warrant intervention based on IVUS alone. Among 68 patients undergoing venous stenting for advanced chronic venous disease, a pre-intervention

Figure 3. *Iliac vein extrinsic compression. IVUS-guidance can be used to evaluate for venous compression and to determine the severity of compression. A) Extrinsic compression of left common iliac vein on venography: lack of contrast flow at site of compression (solid arrow), with prominent pelvic collateral (dotted arrow); B) IVUS determination of aetiology of venous compression: IVUS-guided demonstration of iliac vein compression (blue oval) with parallel view of iliac artery (green arrow) at the site of compression, as seen on venography (Figure 3A, solid arrow). The compressed iliac vein has been traced along the vessel wall to get an estimation of the diameter and area (C) IVUS-guided sizing of the normal reference iliac vein proximal to the stenosis: The reference iliac vein has been traced along the vessel wall to get an estimation of the diameter and area (green circle) proximal to the level of compression; D) IVUS-guided difference between compressed and normal reference veins: the 2 images are superimposed to demonstrate how the differences in areas of the reference and compressed iliac veins can be calculated. The minimum luminal area is divided by the reference luminal area to determine severity of stenosis. As can be seen in the image, there is >50% difference in area estimations suggesting severe compression.*

cross-sectional area reduction of >54% by IVUS best predicted clinical improvement, defined as a >4 point improvement in the revised venous clinical severity score67. However, among the 46 patients undergoing stenting for a cross-sectional area reduction >50% by IVUS, clinical improvement was noted in only 21 patients (positive predictive value 46%). Accordingly, it is difficult to define a threshold stenosis at which a venous stenosis becomes haemodynamically and clinically significant. The determinants of such a "critical" venous stenosis, defined as the degree of stenosis at which upstream pressure increases, are far more complex than in the arterial circulation⁶⁸.

PROCEDURAL PLANNING **(Figure 3)**

Following diagnosis, IVUS is important in planning venous angioplasty and stenting. Critical components of venous stenting include accurate stent sizing and complete stenting of all diseased areas in which IVUS has significant advantages over conventional venography. With respect to stent sizing, many previous recommendations were based upon the use of Wallstents (Boston Scientific) which often required significant oversizing in comparison to the newly approved dedicated venous stents. Based upon a variety of largely theoretical concerns, optimal venous stent diameters of 16-18 mm, 14 mm, and 12 mm have been recommended in the common iliac, external iliac, and common femoral veins, respectively⁶⁹. Although such broad recommendations are useful in the setting of chronic venous occlusions, in which case a normal adjacent vessel may be unavailable for measurement, if possible, these recommendations should be interpreted in the context of IVUSguided measurements of the normal, adjacent reference vessel and stent sizes should be adjusted appropriately. Complete coverage of all disease, without skip areas, is also a fundamental tenet of venous stenting, and IVUS has significant advantages over venography in detecting subtle irregularities of the venous lumen, particularly in the setting of post-thrombotic disease. In a blinded review of 152 patients undergoing endovascular intervention for chronic iliofemoral vein stenosis in 155 limbs, IVUS was used both for disease assessment and determining the optimal landing zones for deep venous stenting. Compared with venography, IVUS was better able to detect maximal area stenosis, anatomic location of maximal stenosis, ilio-caval confluence location and distal landing zones⁷⁰. This is more accurate than the traditional use of body landmarks with venography to guide venous stenting. POST-INTERVENTION EVALUATION AND OPTIMISATION

(Figure 4)

IVUS may be useful in assessing and optimising the results of venous stenting. Although completion venography is helpful in documenting decompression of venous collaterals, subjective venous flow and resolution of contrast stagnation, IVUS is an invaluable adjunct, allowing assessment of stent sizing, wall apposition and absence of residual compressive or stenotic lesions. IVUS is helpful in visualising areas of residual obstruction that are poorly visualised on venography and may be more accurate than venography in assessing apposition of adjacent stents⁷⁰. Furthermore, in a study of 274 previously stented limbs undergoing re-stenting of the ilio-caval

Figure 4. *Completion IVUS following bilateral ilio-caval venous stenting can be used to evaluate for optimal stent expansion. A) Venography following bilateral iliac vein stenting; B) IVUS demonstrating well-expanded left iliac vein stent at the left ilio-caval junction; C) IVUS demonstrating right iliac vein stent collapsing due to lack of radial resistive force at the right ilio-caval junction, not readily apparent on venography (Figure 4A).*

vein, IVUS-guided overdilation of the stent resulted in significantly better area improvement compared with no overdilation⁷¹.

Although IVUS has been most extensively used in the evaluation of chronic venous obstruction, it could have a role in interventional treatment of acute iliofemoral venous thrombosis, in particular in determining device selection. In a study of 33 patients with iliofemoral deep vein thrombosis undergoing pharmacomechanical thrombectomy, IVUS more precisely measured post-procedural segment volume versus venography alone⁷². Similarly, IVUS distinguished significant residual thrombus, stenosis or May-Thurner anatomy requiring additional interventions in 100% of patients versus 48% evaluated with venography alone⁷².

The role of IVUS may involve longitudinal evaluation following intervention. Although non-invasive imaging is typically employed first, IVUS can be used when there is ambiguity on imaging in the context of persistent clinical symptoms or if clinical suspicion for device failure is high enough. IVUS has been used in the routine surveillance of stent obstruction in ilio-caval veins⁷³, assessment of midterm patency of stents placed for non-thrombotic iliac vein lesions74 and evaluation of long-term patency of ilio-caval stenting in patients with chronic venous insufficiency⁷⁵.

Conclusions

IVUS has become an important adjunctive imaging tool during peripheral arterial and venous intervention. Although limited

prospective data exist, its safety profile and demonstration of improving procedural outcomes during PCI support its use during peripheral intervention. The current application of peripheral IVUS in clinical practice includes vessel measurement, pre- and post-procedural planning, stent optimisation, and detection of thrombus, dissection or calcium severity. Future work needs to address how to better streamline and implement IVUS use into clinical practice in order to improve rates of adoption.

Acknowledgements

We would like to acknowledge Sahana Natesan, BS, Shylie Ati, BA and Joanna Suomi, AB, MSc for their assistance in preparing and proofing the manuscript.

Funding

E. Secemsky is funded in part by NIH/NHLBI K23HL150290. This review was funded in part by unrestricted educational grants to the Beth Israel Deaconess Medical Center from Boston Scientific and Philips IGT. These companies have not seen or participated in the creation of this manuscript, including in the writing of the manuscript, significant edits and the decision whether to submit.

Conflict of interest statement

E. Secemsky is part of the Speakers Bureau, is a consultant for and is on the Advisory Board of Bard, Cook, CSI, Janssen, Medtronic, and Philips; receives grants to his institution from AstraZeneca, Bard, Boston Scientific, Cook, CSI, Medtronic, and Philips. S. Parikh conducts institutional research for and is a DSMB at Boston Scientific; a Global PI at Abbott; and a National PI at Veryan Medical; has received institutional consulting fees from Abiomed, Inari, Penumbra, Terumo, and Canon; and is on the advisory board for Abbott, Boston Scientific, CSI, Medtronic, Philips, and Cordis. He also conducts research for Abbott, Boston Scientific (DSMB), Shockwave, TriReme, and Veryan Medical. M. Kohi is a board member at VIVA Physicians and is a Deputy Editor for the Journal of Vascular and Interventional Radiology. She is also a Global PI of the ELEGANCE registry with Boston Scientific but is not being personally compensated. M. Lichtenberg receives research funding from Cagent Vascular, Biotronik, Boston Scientific, Veryan, PlusMedica, Philips, and CR Bard; honoraria for lectures from Cagent Vascular, CR Bard, Boston Scientific, AB Medical, Philips, Terumo, Biotronik, Veryan, and Medtronic; honoraria for advisory board activities from Cagent Vascular, Biotronik, Veryan, Boston Scientific, Philips, Soundbite, Limflow, Covellus, and Medtronic; and participates in clinical trials for Cagent Vascular, Biotronik, Veryan, Boston Scientific, Philips, Limflow, Terumo, and CR Bard. M. Meissner discloses that he has served as a consultant for Cook Medical for a project using a Delphi consensus panel for venous stenting. R. Varcoe consults for Medtronic, Abbott, BD Bard, Philips, Intervene, and Surmodics. A. Holden receives consulting fees as a Medical Advisory Board member from Medtronic, Boston Scientific, Gore,

and Philips. M. Jaff is a part-time employee at Boston Scientific; a consultant at Glide Healthcare; and has equity investments in R3 Vascular, Nectero, Vactronix, and Efemoral. D. Chalyan is an employee at Philips IGT. D. Clair has stock options at Nectero Inc.; discloses his involvement with Boston Scientific, Elastimed, Endologix, and Medtronic; and clarifies that he does not receive any income from these relationships as all the income goes to the organisation by whom he is employed. He also serves as a Data and Safety Monitoring Board member for Bard/BD and Boston Scientific where all income goes to the medical organisation. B. Hawkins receives consulting fees from Baim and conducts institutional research for Behring, Hemostemix, and NIH/ NHLBI. K. Rosenfield receives grants to his institution from NIH and Boston Scientific; has equity in Accolade, Access Vascular, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMD, JanaCare, Magneto, Neptune Medical, Orchestra, PQ Bypass, Shockwave, Summa Therapeutics, Thrombolex, Truvic, and Valcare; receives consulting fees from and is a board member at Angiodynamics, Boston Scientific, Getinge-Atrium, Contego, Mayo Clinic, Neptune Medical, Philips, Summa Therapeutics, Surmodics, Thrombolex, and Truvic. He is also on the scientific advisory board for Angiodynamics, Boston Scientific, Contego, InspireMD, Janssen, Magneto, Neptune Medical, Philips, Summa Therapeutics, Surmodics, Thrombolex, and Truvic; is a board member of the National PERT Consortium™, a not-for-profit 501c3 organisation dedicated to advancing treatment and improving outcomes in pulmonary embolism; and conducts institutional research for NIH/NHLBI.

References

1. Lee JT, Fang TD, White RA. Applications of intravascular ultrasound in the treatment of peripheral occlusive disease. *Semin Vasc Surg.* 2006;19:139-44.

2. Elgendy IY, Gad M, Mintz GS. Meta-Analysis of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation for Left Main Coronary Disease. *Am J Cardiol.* 2020;128:92-3.

3. Buccheri S, Franchina G, Romano S, Puglisi S, Venuti G, D'Arrigo P, Francaviglia B, Scalia M, Condorelli A, Barbanti M, Capranzano P, Tamburino C, Capodanno D. Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis Of 31 Studies and 17,882 Patients. *JACC Cardiovasc Interv.* 2017;10:2488-98.

4. Ye Y, Yang M, Zhang S, Zeng Y. Percutaneous coronary intervention in left main coronary artery disease with or without intravascular ultrasound: A meta-analysis. *PLoS One.* 2017;12:e0179756.

5. Räber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, Meneveau N, de la Torre Hernandez JM, Escaned J, Hill J, Prati F, Colombo A, Di Mario C, Regar E, Capodanno D, Wijns W, Byrne RA, Guagliumi G. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. *EuroIntervention.* 2018;14:656-77.

6. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol.* 2001;37:1478-92.

7. Shammas NW, Radaideh Q, Shammas WJ, Daher GE, Rachwan RJ, Radaideh Y. The role of precise imaging with intravascular ultrasound in coronary and peripheral interventions. *Vasc Health Risk Manag.* 2019;15:283-90.

8. Loffroy R, Falvo N, Galland C, Fréchier L, Ledan F, Midulla M, Chevallier O. Intravascular Ultrasound in the Endovascular Treatment of Patients With Peripheral

Arterial Disease: Current Role and Future Perspectives. *Front Cardiovasc Med.* 2020;7:551861.

9. Sheikh AB, Anantha-Narayanan M, Smolderen KG, Jelani QU, Nagpal S, Schneider M, Llanos F, Ionescu C, Regan C, Attaran R, Altin SE, Mena-Hurtado C. Utility of Intravascular Ultrasound in Peripheral Vascular Interventions: Systematic Review and Meta-Analysis. *Vasc Endovascular Surg.* 2020;54:413-22.

10. Nishanian G, Kopchok GE, Donayre CE, White RA. The impact of intravascular ultrasound (IVUS) on endovascular interventions. *Semin Vasc Surg.* 1999;12:285-99.

11. Marrocco CJ, Jaber R, White RA, Walot I, DeVirgilio C, Donayre CE, Kopchok G. Intravascular ultrasound. *Semin Vasc Surg.* 2012;25:144-52.

12. Garcìa-Garcìa HM, Gogas BD, Serruys PW, Bruining N. IVUS-based imaging modalities for tissue characterization: similarities and differences. *Int J Cardiovasc Imaging.* 2011;27:215-24.

13. Nadkarni SK, Austin H, Mills G, Boughner D, Fenster A. A pulsating coronary vessel phantom for two- and three-dimensional intravascular ultrasound studies. *Ultrasound Med Biol.* 2003;29:621-8.

14. Leu HJ, Vogt M, Pfrunder H. Morphological alterations of non-varicose and varicose veins. (A morphological contribution to the discussion on pathogenesis of varicose veins). *Basic Res Cardiol.* 1979;74:435-44.

15. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med.* 1987;316: 1371-5.

16. Ahn JM, Kang SJ, Yoon SH, Park HW, Kang SM, Lee JY, Lee SW, Kim YH, Lee CW, Park SW, Mintz GS, Park SJ. Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies. *Am J Cardiol.* 2014;113:1338-47.

17. Mentias A, Sarrazin MV, Saad M, Panaich S, Kapadia S, Horwitz PA, Girotra S. Long-Term Outcomes of Coronary Stenting With and Without Use of Intravascular Ultrasound. *JACC Cardiovasc Interv.* 2020;13:1880-90.

18. Hausmann D, Erbel R, Alibelli-Chemarin Marie J, Boksch W, Caracciolo E, Cohn Joel M, Culp Stephen C, Daniel Werner G, De Scheerder I, DiMario C, Ferguson James J, Fitzgerald Peter J, Friedrich G, Ge J, Görge G, Hanrath P, Mc BHJ, Isner Jeffrey M, Jain S, Maier-Rudolph W, Mooney M, Moses Jeffrey W, Mudra H, Pinto Fausto J, Smalling Richard W, Talley JD, Tobis Jonathan M, Walter Paul D, Weidinger F, Werner Gerald S, Yeung Alan C, Yock Paul G. The safety of intracoronary ultrasound. A multicenter survey of 2207 examinations. *Circulation.* 1995;91:623-30.

19. Guédès A, Keller PF, L'Allier PL, Lespérance J, Grégoire J, Tardif JC. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. *J Am Coll Cardiol.* 2005;45:559-64.

20. Batkoff BW, Linker DT. Safety of intracoronary ultrasound: data from a Multicenter European Registry. *Cathet Cardiovasc Diagn.* 1996;38:238-41.

21. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/ SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation.* 2011;124:e574-651.

22. Lotfi A, Jeremias A, Fearon WF, Feldman MD, Mehran R, Messenger JC, Grines CL, Dean LS, Kern MJ, Klein LW; Society of Cardiovascular Angiography and Interventions. Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv.* 2014;83:509-18.

23. Arthurs ZM, Bishop PD, Feiten LE, Eagleton MJ, Clair DG, Kashyap VS. Evaluation of peripheral atherosclerosis: a comparative analysis of angiography and intravascular ultrasound imaging. *J Vasc Surg*. 2010;51:933-8.

24. Neuerburg J, Vorwerk D, Günther RW, Keulers P. Intravaskulärer Ultraschall zur Unterstützung perkutaner interventioneller Eingriffe. [Intravascular ultrasound for support in percutaneous interventional treatment]. [Article in German]. *Vasa Suppl.* 1991;33:298-9.

25. Marteslo JP, Makary MS, Khabiri H, Flanders V, Dowell JD. Intravascular Ultrasound for the Peripheral Vasculature-Current Applications and New Horizons. *Ultrasound Med Biol.* 2020;46:216-24.

26. Pavillard E, Sewall L. A post-market, multi-vessel evaluation of the imaging of peripheral arteries for diagnostic purposeS comparing optical Coherence tomogrApy and iNtravascular ultrasound imaging (SCAN). *BMC Med Imaging.* 2020;20:18.

27. Kendrick DE, Allemang MT, Gosling AF, Nagavalli A, Kim AH, Nishino S, Parikh SA, Bezerra HG, Kashyap VS. Dextran or Saline Can Replace Contrast for Intravascular Optical Coherence Tomography in Lower Extremity Arteries. *J Endovasc Ther.* 2016;23:723-30.

28. Secco GG, Grattoni C, Parisi R, Micari A, Oshoala K, Cremonesi A, Fattori R, Zeller T, Castriota F. Saline vs contrast infusion during optical coherence tomography imaging of peripheral percutaneous intervention. *Int J Cardiol.* 2014;172:246-8.

29. Babaev A, Zavlunova S, Attubato MJ, Martinsen BJ, Mintz GS, Maehara A. Orbital Atherectomy Plaque Modification Assessment of the Femoropopliteal Artery Via Intravascular Ultrasound (TRUTH Study). *Vasc Endovascular Surg.* 2015;49: 188-94.

30. Maehara A, Mintz GS, Shimshak TM, Ricotta JJ 2nd, Ramaiah V, Foster MT 3rd, Davis TP, Gray WA. Intravascular ultrasound evaluation of JETSTREAM atherectomy removal of superficial calcium in peripheral arteries. *EuroIntervention.* 2015;11: 96-103.

31. Singh T, Koul D, Szpunar S, Torey J, Dhabuwala J, Saigh L, Pires LA, Davis T. Tissue removal by ultrasound evaluation (the TRUE study): the Jetstream G2 system post-market peripheral vascular IVUS study. *J Invasive Cardiol.* 2011;23:269-73.

32. Hassan AH, Ako J, Waseda K, Honda Y, Zeller T, Leon MB, Fitzgerald PJ. Mechanism of lumen gain with a novel rotational aspiration atherectomy system for peripheral arterial disease: examination by intravascular ultrasound. *Cardiovasc Revasc Med.* 2010;11:155-8.

33. Bishop PD, Feiten LE, Ouriel K, Nassoiy SP, Pavkov ML, Clair DG, Kashyap VS. Arterial calcification increases in distal arteries in patients with peripheral arterial disease. *Ann Vasc Surg.* 2008;22:799-805.

34. Suh WM, Seto AH, Margey RJ, Cruz-Gonzalez I, Jang IK. Intravascular detection of the vulnerable plaque. *Circ Cardiovasc Imaging.* 2011;4:169-78.

35. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff MW. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). *J Am Coll Cardiol.* 2015;65:931-41.

36. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. *Catheter Cardiovasc Interv.* 2014;83: E212-20.

37. Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, Shammas NW, Clair D; DEFINITIVE Ca++ Investigators. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca++ trial. *Catheter Cardiovasc Interv.* 2014;84:236-44.

38. Yin D, Maehara A, Shimshak TM, Ricotta JJ 2nd, Ramaiah V, Foster MT 3rd, Davis TP, Matsumura M, Mintz GS, Gray WA. Intravascular Ultrasound Validation of Contemporary Angiographic Scores Evaluating the Severity of Calcification in Peripheral Arteries. *J Endovasc Ther.* 2017;24:478-87.

39. Fujihara M, Kozuki A, Tsubakimoto Y, Takahara M, Shintani Y, Fukunaga M, Iwasaki Y, Nakama T, Yokoi Y. Lumen Gain After Endovascular Therapy in Calcified Superficial Femoral Artery Occlusive Disease Assessed by Intravascular Ultrasound (CODE Study). *J Endovasc Ther.* 2019;26:322-30.

40. Shammas NW, Dippel EJ, Shammas G, Gayton L, Coiner D, Jerin M. Dethrombosis of the lower extremity arteries using the power-pulse spray technique in patients with recent onset thrombotic occlusions: results of the DETHROMBOSIS Registry. *J Endovasc Ther.* 2008;15:570-9.

41. Hagenaars T, A Po IF, van Sambeek MR, Coen VL, Van Tongeren RB, Gescher FM, Wittens CH, Boelhouwer RU, Pattynama PM, Gussenhoven EJ. Gamma radiation induces positive vascular remodeling after balloon angioplasty: a prospective, randomized intravascular ultrasound scan study. *J Vasc Surg*. 2002;36:318-24.

42. Hitchner E, Zayed M, Varu V, Lee G, Aalami O, Zhou W. A prospective evaluation of using IVUS during percutaneous superficial femoral artery interventions. *Ann Vasc Surg.* 2015;29:28-33.

43. Kashyap VS, Pavkov ML, Bishop PD, Nassoiy SP, Eagleton MJ, Clair DG, Ouriel K. Angiography underestimates peripheral atherosclerosis: lumenography revisited. *J Endovasc Ther.* 2008;15:117-25.

44. Saket RR, Razavi MK, Padidar A, Kee ST, Sze DY, Dake MD. Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection. *J Endovasc Ther.* 2004; 11:274-80.

45. Baker AC, Humphries MD, Noll RE Jr, Salhan N, Armstrong EJ, Williams TK, Clouse WD. Technical and early outcomes using ultrasound-guided reentry for chronic total occlusions. *Ann Vasc Surg.* 2015;29:55-62.

46. Takahashi Y, Sato T, Okazaki H, Nozaki A, Matsushita M, Kamiya M, Shimizu W. Transvenous Intravascular Ultrasound-Guided Endovascular Treatment for Chronic Total Occlusion of the Infrainguinal Arteries. *J Endovasc Ther.* 2017;24:718-26.

47. Kuku KO, Garcia-Garcia HM, Koifman E, Kajita AH, Desale S, Azizi V, Melaku G, Bui A, Meirovich YF, Beyene S, Dheendsa A, Schneider B, Waksman R; CELLO study

investigators. Intravascular ultrasound assessment of the effect of laser energy on the arterial wall during the treatment of femoro-popliteal lesions: a CliRpath excimer laser system to enlarge lumen openings (CELLO) registry study. *Int J Cardiovasc Imaging.* 2018;34:345-52.

48. Shammas NW, Torey JT, Shammas WJ, Jones-Miller S, Shammas GA. Intravascular Ultrasound Assessment and Correlation With Angiographic Findings Demonstrating Femoropopliteal Arterial Dissections Post Atherectomy: Results From the iDissection Study. *J Invasive Cardiol.* 2018;30:240-4.

49. Shammas NW, Shammas WJ, Jones-Miller S, Radaideh Q, Shammas GA. Femoropopliteal Arterial Dissections Post Flex Vessel Prep and Adjunctive Angioplasty: Results of the Flex iDissection Study. *J Invasive Cardiol.* 2019;31: 121-6.

50. Shammas NW, Shammas WJ, Jones-Miller S, Torey JT, Armstrong EJ, Radaideh Q, Shammas GA. Optimal Vessel Sizing and Understanding Dissections in Infrapopliteal Interventions: Data From the iDissection Below the Knee Study. *J Endovasc Ther.* 2020;27:575-80.

51. Shammas NW, Torey JT, Shammas WJ. Dissections in Peripheral Vascular Interventions: A Proposed Classification Using Intravascular Ultrasound. *J Invasive Cardiol.* 2018;30:145-6.

52. Krishnan P, Tarricone A, Ali Z, Purushothaman KR, Overbey J, Vasquez M, Wiley J, Kapur V, Gujja K, Atallah RT, Nasiadko K, Kini A, Sharma S. Intravascular Ultrasound Is an Effective Tool for Predicting Histopathology-Confirmed Evidence of Adventitial Injury Following Directional Atherectomy for the Treatment of Peripheral Artery Disease. *J Endovasc Ther.* 2016;23:672-3.

53. Tarricone A, Ali Z, Rajamanickam A, Gujja K, Kapur V, Purushothaman KR, Purushothaman M, Vasquez M, Zalewski A, Parides M, Overbey J, Wiley J, Krishnan P. Histopathological Evidence of Adventitial or Medial Injury Is a Strong Predictor of Restenosis During Directional Atherectomy for Peripheral Artery Disease. *J Endovasc Ther.* 2015;22:712-5.

54. Navarro F, Sullivan TM, Bacharach JM. Intravascular ultrasound assessment of iliac stent procedures. *J Endovasc Ther.* 2000;7:315-9.

55. Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T, Nanto S, Uematsu M. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions. *J Endovasc Ther.* 2014;21:485-92.

56. Gussenhoven EJ, van der Lugt A, Pasterkamp G, van den Berg FG, Sie LH, Vischjager M, The SH, Li W, Pieterman H, van Urk H. Intravascular ultrasound predictors of outcome after peripheral balloon angioplasty. *Eur J Vasc Endovasc Surg.* 1995;10:279-88.

57. Vogt KC, Just S, Rasmussen JG, Schroeder TV. Prediction of outcome after femoropopliteal balloon angioplasty by intravascular ultrasound. *Eur J Vasc Endovasc Surg.* 1997;13:563-8.

58. Mori S, Hirano K, Nakano M, Muramatsu T, Tsukahara R, Ito Y, Ishimori H. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis. *J Endovasc Ther.* 2015;22: 341-9.

59. Kurata N, Iida O, Asai M, Masuda M, Okamoto S, Ishihara T, Nanto K, Mano T. Factors Influencing in-Stent Occlusion after Femoropopliteal Artery Stent Placement with Intravascular Ultrasound Evaluation. *J Vasc Interv Radiol.* 2020;31:213-20.

60. Miki K, Fujii K, Fukunaga M, Nishimura M, Horimatsu T, Saita T, Tamaru H, Imanaka T, Shibuya M, Naito Y, Masuyama T. Impact of intravascular ultrasound findings on long-term patency after self-expanding nitinol stent implantation in the iliac artery lesion. *Heart Vessels.* 2016;31:519-27.

61. Miki K, Fujii K, Kawasaki D, Shibuya M, Fukunaga M, Imanaka T, Tamaru H, Sumiyoshi A, Nishimura M, Horimatsu T, Saita T, Okada K, Kimura T, Honda Y, Fitzgerald PJ, Masuyama T, Ishihara M. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery. *J Endovasc Ther.* 2016;23:424-32.

62. Miki K, Fujii K, Tanaka T, Yanaka K, Yoshihara N, Nishimura M, Sumiyoshi A, Horimatsu T, Imanaka T, Fukunaga M, Akahori H, Masuyama T, Ishihara M. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions. *J Endovasc Ther.* 2020;27:77-85.

63. Iida O, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, Kawasaki D, Nanto S, Yokoi H, Uematsu M; ZEPHYR Investigators. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis. *JACC Cardiovasc Interv.* 2015;8:1105-12.

64. Lau I, Png CYM, Eswarappa M, Miller M, Kumar S, Tadros R, Vouyouka A, Marin M, Faries P, Ting W. Defining the utility of anteroposterior venography in the diagnosis of venous iliofemoral obstruction. *J Vasc Surg Venous Lymphat Disord.* 2019;7:514-21.

65. Neglén P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg*. 2002;35:694-700.

66. Gagne PJ, Tahara RW, Fastabend CP, Dzieciuchowicz L, Marston W, Vedantham S, Ting W, Iafrati MD. Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. *J Vasc Surg Venous Lymphat Disord.* 2017;5: 678-87.

67. Gagne PJ, Gasparis A, Black S, Thorpe P, Passman M, Vedantham S, Marston W, Iafrati M. Analysis of threshold stenosis by multiplanar venogram and intravascular ultrasound examination for predicting clinical improvement after iliofemoral vein stenting in the VIDIO trial. *J Vasc Surg Venous Lymphat Disord.* 2018;6:48-56.e1.

68. Raju S, Kirk O, Davis M, Olivier J. Hemodynamics of "critical" venous stenosis and stent treatment. *J Vasc Surg Venous Lymphat Disord.* 2014;2:52-9.

69. Raju S, Buck WJ, Crim W, Jayaraj A. Optimal sizing of iliac vein stents. *Phlebology.* 2018;33:451-7.

70. Montminy ML, Thomasson JD, Tanaka GJ, Lamanilao LM, Crim W, Raju S. A comparison between intravascular ultrasound and venography in identifying key parameters essential for iliac vein stenting. *J Vasc Surg Venous Lymphat Disord.* 2019;7:801-7.

71. Raju S, Knight A, Buck W, May C, Jayaraj A. Caliber-targeted reinterventional overdilation of iliac vein Wallstents. *J Vasc Surg Venous Lymphat Disord.* 2019;7: 184-94.

72. Murphy EH, Broker HS, Johnson EJ, Modrall JG, Valentine RJ, Arko FR 3rd. Device and imaging-specific volumetric analysis of clot lysis after percutaneous mechanical thrombectomy for iliofemoral DVT. *J Endovasc Ther.* 2010;17:423-33.

73. Sebastian T, Barco S, Engelberger RP, Spirk D, Schindewolf M, Baumann F, Baumgartner I, Kucher N. Duplex Ultrasound Investigation for the Detection of Obstructed Iliocaval Venous Stents. *Eur J Vasc Endovasc Surg.* 2020;60:443-50.

74. Rizvi SA, Ascher E, Hingorani A, Marks N. Stent patency in patients with advanced chronic venous disease and nonthrombotic iliac vein lesions. *J Vasc Surg Venous Lymphat Disord.* 2018;6:457-63.

75. Raju S, Darcey R, Neglén P. Iliac-caval stenting in the obese. *J Vasc Surg*. 2009;50: 1114-20.